Core One Labs’ Upgrades to OTCQB Venture Market
April 06, 2022 08:30 ET
|
Core One Labs Inc.
VANCOUVER, British Columbia, April 06, 2022 (GLOBE NEWSWIRE) -- Core One Labs Inc. (CSE: “COOL”), (OTCQB: “CLABF”), (Frankfurt: LD6, WKN: A3CSSU) (the “Company” or “Core One”) a life sciences...
Core One Labs to Investigate Soliciting Investment and Potential Takeover Opportunities
March 19, 2022 19:55 ET
|
Core One Labs Inc.
VANCOUVER, British Columbia, March 19, 2022 (GLOBE NEWSWIRE) -- Core One Labs Inc. (CSE: COOL), (OTC: CLABF), (Frankfurt: LD6, WKN: A3CSSU) (the “Company” or “Core One”) announces that following its...
Core One Labs’ Akome Biotech Initiates Neurogenesis Stimulation and Modeling Studies: Advancing its Proprietary Psychedelic-based Pharmaceutical Formulations
March 04, 2022 03:00 ET
|
Core One Labs Inc.
VANCOUVER, British Columbia, March 04, 2022 (GLOBE NEWSWIRE) -- Core One Labs Inc. (CSE: COOL), (OTC: CLABF), (Frankfurt: LD6, WKN: A3CSSU) (the “Company” or “Core One”) is pleased to announce that...
Core One Labs’ Files Milestone Patent for Protection of its Recombinant Production System for Optimized Biosynthetic N-methyltryptamine (NMT)
February 21, 2022 16:00 ET
|
Core One Labs Inc.
VANCOUVER, British Columbia, Feb. 21, 2022 (GLOBE NEWSWIRE) -- Core One Labs Inc. (CSE: COOL), (OTC: CLABF), (Frankfurt: LD6, WKN: A3CSSU) (“Core One” or the “Company”) is pleased to announce that...
Core One Labs Announces Successful Proof of Concept and Files Patent for Protection of its Recombinant Production System for Optimized Biosynthesis of Psilocybin
January 21, 2022 16:22 ET
|
Core One Labs Inc.
VANCOUVER, British Columbia, Jan. 21, 2022 (GLOBE NEWSWIRE) -- Core One Labs Inc. (CSE: COOL), (OTC: CLABF), (Frankfurt: LD6, WKN: A3CSSU) (“Core One” or the “Company”) is pleased to announce that...
Core One Labs Special Investor Webcast Rescheduled to Friday, January 21, 2022
January 18, 2022 13:00 ET
|
Core One Labs Inc.
VANCOUVER, British Columbia, Jan. 18, 2022 (GLOBE NEWSWIRE) -- Core One Labs Inc. (CSE: COOL), (OTC: CLABD), (Frankfurt: LD6, WKN: A3CSSU) (“Core One” or the “Company”) announces that the special...
Core One Labs’ Clinics Submit Application to Treat Patient With Psilocybin Psychedelic-Assisted Therapy
August 13, 2021 02:55 ET
|
Core One Labs Inc.
VANCOUVER, British Columbia, Aug. 13, 2021 (GLOBE NEWSWIRE) -- Core One Labs Inc. (CSE: COOL), (OTC: CLABD), (Frankfurt: LD6, WKN: A3CSSU) (the “Company”) a research and technology company focused...
Core One Labs’ Virtual Town Hall Reveals Company is Nearing Production of Biosynthesized Psilocybin: Breakthrough In the Psychedelic Space Expected Upon Successful Completion
August 05, 2021 01:15 ET
|
Core One Labs Inc.
VANCOUVER, British Columbia, Aug. 04, 2021 (GLOBE NEWSWIRE) -- Core One Labs Inc. (CSE: COOL), (OTC: CLABD), (Frankfurt: LD6, WKN: A3CSSU) (the “Company” or “Core One”) is a research and development...
Core One Labs’ Vocan Initiates Engineering and Design of a Proprietary Production System for Manufacturing of API-Grade DMT
April 21, 2021 04:05 ET
|
Core One Labs Inc.
VANCOUVER, British Columbia, April 21, 2021 (GLOBE NEWSWIRE) -- Core One Labs Inc. (CSE: COOL), (OTC: CLABF), (Frankfurt: LD62, WKN: A2P8K3) (the “Company” or ”Core One”) a life sciences research...